The shelves of any chemist now carry probiotic drops, sachets, and powders aimed at babies, with claims that span colic, immunity, eczema, digestion, sleep, and almost anything else parents are tired enough to consider. Some of these claims have meaningful research behind them. Many do not.
The evidence base for infant probiotics is genuinely complex — what works depends on the specific strain, the specific condition, and often the feeding method. Knowing which probiotic claims have actual trial support, and which strain to look for on the label, lets you make a useful decision rather than a hopeful one.
Healthbooq gives parents evidence-based guidance on infant health and nutrition, with the marketing language stripped out.
What Probiotics Actually Are
Probiotics are live microorganisms — almost always bacteria, occasionally yeasts — that, when given in sufficient quantities, may produce a health benefit. The strains most commonly used for infants come from the Lactobacillus and Bifidobacterium genera, and from the yeast Saccharomyces boulardii.
The single most important point about probiotics is that effects are strain-specific. The effect of one strain of Lactobacillus rhamnosus cannot be assumed to apply to another strain of the same species, never mind to Lactobacillus acidophilus. This is not pedantry — it is the practical reason that one bottle on the chemist shelf may have research behind it and the bottle next to it, with the same species name, may have none.
Strain identifiers look like "DSM 17938" or "ATCC 55730" — alphanumeric codes after the species name. A label that says only "Lactobacillus reuteri" without a strain code cannot be matched against the trials. This is true even if the marketing material implies otherwise.
What the Evidence Actually Supports
Colic in breastfed infants. This is the strongest evidence for any infant probiotic indication. Multiple randomised controlled trials of Lactobacillus reuteri DSM 17938 have found that giving five drops a day reduces daily crying time by around 50 minutes to an hour compared with placebo, in breastfed babies with colic. The effect is real and large enough to matter to a parent who is exhausted. Three caveats:
- The evidence is consistently positive in breastfed colicky babies. In formula-fed babies, results are mixed and several trials show no effect.
- The benefit is modest in absolute terms — colic still exists, the baby still cries, just less.
- The strain matters. DSM 17938 is the strain in BioGaia ProTectis drops and a handful of other branded products. A "Lactobacillus reuteri" without DSM 17938 on the label is not the strain studied.
Antibiotic-associated diarrhoea. Both Lactobacillus rhamnosus GG and Saccharomyces boulardii have evidence from paediatric trials of reducing the loose stools that often follow a course of antibiotics. Given how many courses of antibiotics children receive in the first few years, this is a practically useful application — a probiotic given alongside an antibiotic course can reduce the duration and severity of diarrhoea by a couple of days.
Acute infectious gastroenteritis. Evidence here is more mixed than it once looked. Older trials suggested probiotics shortened acute diarrhoea by about a day; more recent, larger trials (notably the PROGUT and PERC trials in 2018) found no clinically meaningful benefit. NICE and ESPGHAN guidance has accordingly become more cautious. Probiotics are not the wrong choice here, but the case for them is weaker than it was.
Eczema prevention. The picture is mixed and currently insufficient for a routine recommendation. Some trials in babies at high risk of allergy (those with a strong family history) have suggested modest preventive effects with specific strains given to mother in late pregnancy and to infant in early life, but pooled analyses are inconsistent and current UK guidelines do not recommend routine probiotics for eczema prevention.
Necrotising enterocolitis (NEC) in premature infants. This is a separate clinical territory that families of premature babies will encounter — there is good evidence that certain probiotic preparations reduce NEC risk in preterm infants in NICU. This is a hospital decision, not a parent decision, and the strains and products used are specific.
What About the Microbiome More Broadly
A baby's gut microbiome is shaped by mode of birth (vaginal vs caesarean), feeding (breast vs formula), early antibiotic exposure, weaning diet, and the home environment. Breast milk itself is a major source of microorganisms and of human milk oligosaccharides (HMOs) — sugars that the baby cannot digest, but that selectively feed beneficial gut bacteria, particularly Bifidobacteria. Breastfed babies have characteristically different microbiomes from formula-fed babies, with much higher Bifidobacteria counts in the first months.
Whether the differences in microbiome composition between groups translate into long-term health differences is an active research area. The honest answer is: there are interesting associations (allergy, autoimmune, metabolic) but causal evidence is still building, and "fixing" the microbiome with off-the-shelf probiotics is not yet a thing the evidence supports doing on a population level. The microbiome conversation is not a reason to give a healthy term baby a probiotic; the trial-supported indications above are.
Practical Points
- For a breastfed colicky baby where the colic is bothering the family, a 2–4 week trial of Lactobacillus reuteri DSM 17938 (e.g. five drops once daily) is a reasonable thing to try. If there is no improvement in 2–3 weeks, stop.
- Alongside an antibiotic course, Lactobacillus rhamnosus GG or Saccharomyces boulardii started on the same day and continued for the duration of the course (and a few days after) reduces antibiotic-associated diarrhoea.
- Read the strain code, not the marketing. "Live cultures" without an identified strain on the label is not enough information to know what you are buying.
- Probiotics are generally safe in healthy term infants. They are not recommended in premature infants or in immunocompromised children without specialist input — there are case reports of infections in these groups.
- Speak to a GP or health visitor if you are using a probiotic for a specific concern. They will not always have detailed strain knowledge, but they can flag if your child is in a group where probiotics are not appropriate.
A reasonable rule of thumb: if you cannot find which strain is in the bottle, the bottle is not what you read about in the trials.
Key Takeaways
Probiotic claims for babies are everywhere; the evidence behind them is uneven and strain-specific. The clearest signal is for Lactobacillus reuteri DSM 17938 in breastfed colicky infants, where multiple RCTs show roughly one less hour of crying per day. Specific strains (Lactobacillus rhamnosus GG, Saccharomyces boulardii) help reduce antibiotic-associated diarrhoea in children. Eczema prevention evidence is mixed and not enough to support a routine recommendation. Probiotics are generally safe in healthy term infants but not recommended without specialist guidance for premature or immunocompromised children. The most important thing on a label is the strain — DSM 17938 is not the same as a generic 'Lactobacillus reuteri,' and a product without a strain ID cannot be matched against the research.
